DE602005019050D1 - Auf tumore zielende zellen, die den "tumor necrosis factor-related apoptosis-inducing ligand" (trial) produzieren - Google Patents

Auf tumore zielende zellen, die den "tumor necrosis factor-related apoptosis-inducing ligand" (trial) produzieren

Info

Publication number
DE602005019050D1
DE602005019050D1 DE602005019050T DE602005019050T DE602005019050D1 DE 602005019050 D1 DE602005019050 D1 DE 602005019050D1 DE 602005019050 T DE602005019050 T DE 602005019050T DE 602005019050 T DE602005019050 T DE 602005019050T DE 602005019050 D1 DE602005019050 D1 DE 602005019050D1
Authority
DE
Germany
Prior art keywords
trial
tumor
necrosis factor
produce
apoptosis inducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005019050T
Other languages
German (de)
English (en)
Inventor
Alessandro M Gianni
Carmelo Carlo-Stella
Francesco Colotta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe SpA
Original Assignee
Dompe SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe SpA filed Critical Dompe SpA
Publication of DE602005019050D1 publication Critical patent/DE602005019050D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE602005019050T 2004-07-29 2005-07-21 Auf tumore zielende zellen, die den "tumor necrosis factor-related apoptosis-inducing ligand" (trial) produzieren Expired - Lifetime DE602005019050D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04017907A EP1621550A1 (en) 2004-07-29 2004-07-29 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
PCT/EP2005/007957 WO2006010558A1 (en) 2004-07-29 2005-07-21 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail)

Publications (1)

Publication Number Publication Date
DE602005019050D1 true DE602005019050D1 (de) 2010-03-11

Family

ID=34925971

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005019050T Expired - Lifetime DE602005019050D1 (de) 2004-07-29 2005-07-21 Auf tumore zielende zellen, die den "tumor necrosis factor-related apoptosis-inducing ligand" (trial) produzieren

Country Status (24)

Country Link
US (1) US20070264231A1 (https=)
EP (2) EP1621550A1 (https=)
JP (1) JP5042826B2 (https=)
KR (1) KR20070047757A (https=)
CN (1) CN101076540B (https=)
AT (1) ATE455847T1 (https=)
AU (1) AU2005266543B2 (https=)
BR (1) BRPI0513855A (https=)
CA (1) CA2571426A1 (https=)
DE (1) DE602005019050D1 (https=)
DK (1) DK1771468T3 (https=)
ES (1) ES2340400T3 (https=)
HR (1) HRP20100227T1 (https=)
IL (1) IL180233A (https=)
MX (1) MX2007001152A (https=)
NO (1) NO20070956L (https=)
NZ (1) NZ552223A (https=)
PL (1) PL1771468T3 (https=)
PT (1) PT1771468E (https=)
RS (1) RS51381B (https=)
RU (1) RU2390558C2 (https=)
SI (1) SI1771468T1 (https=)
WO (1) WO2006010558A1 (https=)
ZA (1) ZA200701231B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080199423A1 (en) * 2004-06-18 2008-08-21 Genentech, Inc. Methods of Using Apo2l Receptor Agonists and Ink Cell Activators
DE102006020307A1 (de) * 2006-05-03 2007-11-08 Martin-Luther-Universität Halle-Wittenberg TNF-related apoptosis-including (TRAIL)stabil transgen exprimierende mesenchymale Stammzellen, Verfahren zu ihrer Herstellung und zu ihrer Verwendung
EP2163250B1 (en) * 2007-05-18 2013-01-09 National University Corporation Asahikawa Medical University Anticancer therapy by transplanting vascular endothelial progenitor cells
CN102154213B (zh) * 2011-01-19 2012-07-25 郑骏年 一种运载荷载细胞因子的双调控溶瘤腺病毒的新型cik细胞
JP2015506697A (ja) * 2012-02-01 2015-03-05 ポステック アカデミー‐インダストリー ファウンデーション １２量体ｔｒａｉｌ及びｈｓｖ−ｔｋ自殺遺伝子を同時に発現するベクター並びにそれを用いた抗癌幹細胞治療剤
CN103288966B (zh) * 2013-05-17 2015-01-21 华侨大学 一种融合受体及其用于治疗大肠癌的基因药物
RU2552609C1 (ru) * 2013-10-28 2015-06-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов
AU2015335607B2 (en) 2014-10-24 2020-04-23 Calidi Biotherapeutics (Nevada), Inc. Combination immunotherapy approach for treatment of cancer
US10906951B2 (en) 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
JP6974681B2 (ja) * 2015-07-29 2021-12-01 オーエヌケー セラピューティクス リミテッド 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株
WO2019232631A1 (en) * 2018-06-06 2019-12-12 Stemcell Technologies Canada Inc. Kits, compositions and methods for myeloid-derived suppressor cell enrichment
US12220465B2 (en) 2018-11-28 2025-02-11 Washington University Compositions and methods for targeted treatment and imaging of cancer or tumors
JP2022526504A (ja) * 2019-03-21 2022-05-25 オーエヌケー セラピューティクス リミテッド 細胞死に対する耐性が増大した改変免疫エフェクター細胞
EP3712257A1 (en) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modified natural killer cells with increased resistance to cell death
WO2021209625A1 (en) 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
US6852703B1 (en) * 1997-06-04 2005-02-08 Oxford Biomedica (Uk) Limited Tumor targeted vector
AU2001290720A1 (en) * 2000-09-11 2002-03-26 Musc Foundation For Research Development Method and composition for treating tumors by selective induction of apoptosis
JP2004529102A (ja) * 2000-10-24 2004-09-24 イミュネックス・コーポレーション 併用療法を用いて、腫瘍を治療する方法
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP4493882B2 (ja) * 2001-06-19 2010-06-30 株式会社カネカ 抗原およびこの抗原を識別するモノクローナル抗体

Also Published As

Publication number Publication date
PL1771468T3 (pl) 2010-07-30
HRP20100227T1 (hr) 2010-07-31
CN101076540A (zh) 2007-11-21
MX2007001152A (es) 2007-04-18
RS51381B (sr) 2011-02-28
WO2006010558A8 (en) 2006-08-24
ATE455847T1 (de) 2010-02-15
IL180233A0 (en) 2007-07-04
IL180233A (en) 2010-12-30
NZ552223A (en) 2009-01-31
AU2005266543B2 (en) 2012-02-02
SI1771468T1 (sl) 2010-07-30
WO2006010558A1 (en) 2006-02-02
EP1771468B1 (en) 2010-01-20
ZA200701231B (en) 2008-08-27
PT1771468E (pt) 2010-04-20
CA2571426A1 (en) 2006-02-02
CN101076540B (zh) 2012-10-24
EP1621550A1 (en) 2006-02-01
NO20070956L (no) 2007-02-20
JP2008507961A (ja) 2008-03-21
DK1771468T3 (da) 2010-05-25
KR20070047757A (ko) 2007-05-07
EP1771468A1 (en) 2007-04-11
RU2390558C2 (ru) 2010-05-27
RU2007107369A (ru) 2008-09-10
HK1110874A1 (en) 2008-07-25
US20070264231A1 (en) 2007-11-15
BRPI0513855A (pt) 2008-05-20
JP5042826B2 (ja) 2012-10-03
ES2340400T3 (es) 2010-06-02
AU2005266543A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
DE602005019050D1 (de) Auf tumore zielende zellen, die den "tumor necrosis factor-related apoptosis-inducing ligand" (trial) produzieren
JOP20220079A1 (ar) بروتين ربط متعددة الخصوصية لمعالجة السرطان
CY1118555T1 (el) Γονιδιακη θεραπεια για την αμυοτροφικη πλευρικη σκληρυνση και αλλες διαταραχες της σπονδυλικης στηλης
IL184617A0 (en) Dr5 antibodies and uses thereof
ECSP088299A (es) Modulacion de la expresion del receptor de glucagon
SG170080A1 (en) Human monoclonal antibodies to o8e
CY1118979T1 (el) Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
WO2005118825A3 (en) Chimeric adenoviruses for use in cancer treatment
MX2021015533A (es) Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
EP2175879A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN
WO2007090022A8 (en) Novel compounds for targeting endothelial cells, compositions containing the same and methods for their use
WO2010066046A8 (en) Proliferation-associated modulation of the splicing of the integrin alpha 6 isoforms
EP2386639A3 (en) Modified pore-forming protein toxins and use thereof
WO2006027693A3 (en) Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis
DE602005007220D1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
JOP20250009A1 (ar) جزيئات ارتباط لعلاج السرطان
WO2006088958A3 (en) Encapsulated (chelate or ligand) dendritic polymers
PT1472375E (pt) Produtos génicos expressos diferencialmente em células cancerígenas da mama e seus métodos de utilização
WO2005089123A3 (en) Therapeutic anti-cancer dna
MX2022006278A (es) Proteinas de salmon uk 114 para uso en el tratamiento, diagnostico y prevencion de tumores malignos.
DE60229924D1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
WO2006026451A3 (en) Targeted expression of apoptosis-inducing genes for disease treatment
DE602004032365D1 (de) Modifizierter cea/b7-vektor
WO2006108094A3 (en) Organ homing genes of cancer metastases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition